In this issue of Neurology ® , Hellwig et al. 1 present the results of a large single-center blinded prospective cohort study of consecutively recruited patients (original cohort n ϭ 107) with Lewy body disease (Parkinson disease [PD] or related dementias) and atypical parkinsonian syndromes (APS), including patients with progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and corticobasal degeneration (CBD), who underwent [
18 F]fluorodeoxyglucose (FDG)-PET and postsynaptic D2 receptor [
123 I]iodobenzamide (IBZM)-SPECT imaging at baseline to distinguish APS from Lewy body parkinsonism. Longitudinal clinical assessment performed after a median follow-up of 1 year was used as the gold standard diagnosis. FDG-PET is a radioligand imaging technique to assess regional cerebral glucose metabolism that reflects neuronal and synaptic activities. 2 Cerebral glucose hypometabolism is a characteristic feature of neurodegeneration and is an effective and useful adjunct in the assessment of patients with dementia symptoms. 3 IBZM is a radioligand that estimates the expression of brain postsynaptic dopamine D2-like receptors. 4 The investigators used D2 receptor imaging to help to distinguish idiopathic PD from APS based on relative overexpression of receptors in early PD compared to more prominent receptor losses seen in APS. 4, 5 Accurate APS subclassification, however, cannot be reliably done by D2 receptor imaging studies, which is a limitation of this imaging technique. 4 These radioligands are not approved for clinical use by the Food and Drug Administration in the United States.
Hellwig et al. showed that FDG-PET has higher diagnostic accuracy (94%) for the differential diagnosis of Lewy body parkinsonism vs APS compared to quantitative IBZM-SPECT imaging (74%). The diagnostic accuracy of IBZM-SPECT imaging, however, improved when the analysis was limited to patients with shorter duration of disease (84%) but remained lower than for FDG-PET. Furthermore, Hellwig et al. found that FDG-PET had good specificity in distinguishing APS subtypes. The article confirms findings of previous historical cohort studies 6, 7 and represents a welcome addition to the literature as it represents the largest prospective cohort study supporting Level I American Academy of Neurology Level of Evidence as a test of APS differential diagnosis.
Hellwig and colleagues performed qualitative FDG-PET imaging interpretation based on predefined disease-specific metabolic patterns of cortical and subcortical areas. Readings were further supported by quantitative (cortical) voxel-based analysis based on information of a normal control FDG database, 8 since the diagnostic accuracy of FDG-PET scans can be improved by the use of voxel-based statistical analysis maps. 9 Quantitative image interpretation technologies are increasingly available, particularly in academic and large medical centers. However, all physicians are not necessarily aware of the availability of such technologies, and experience of FDG-PET in a community setting can be disappointing. Increased acceptance of FDG-PET imaging for neurodegenerative disorders probably will require an interdisciplinary approach, with expert readers using the state-of-the-art technologies and discussing scan findings with referring physicians. Diagnostic physicians who are not specialized in molecular brain imaging practice will also need to increase their knowledge of APS and associated metabolic patterns, in order to render reliable scan interpretations.
Resting state FDG-PET scans can be analyzed using more sophisticated statistical methods, such as support vector machine analysis and principal component analysis. 7, 10 Principal component and vector machine analysis, one of the multivariate correlation analysis methods, is used to characterize intercorrelated regional metabolic changes that may be specific for APS subtypes, providing a reader-independent diagnosis. 7 These methods use computer algorithms to analyze scan data from patients with a specific disease and control subjects and define disease-specific metabolic patterns or provide diagnostic classification functions. Disease-specific patterns can be quantitatively expressed as a numerical network score, allowing quantitative comparison of FDG-PET scan findings to track progression of disease or assess response to treatment. Although Hellwig and colleagues show utility of FDG-PET for the differential diagnosis of APS, their reader-based scan analysis approach may have limited diagnostic utility in distinguishing patients with idiopathic PD without dementia from normal controls. In this respect, a FDG-PET network analysis approach may have better diagnostic potential for this indication. 6 More research is needed to establish standardized and objective scan interpretation methods, not only for FDG-PET, but also for other types of molecular brain imaging.
Another limitation of the study is that 17 patients were excluded due to final diagnoses other than Lewy body parkinsonism or APS. Clearly, not all neurodegenerative disorders can be prototypically classified within a single disease entity; multiple pathologies may be present, often confounded by comorbidities that may affect gait or balance. Furthermore, clinical phenotypic variations within a diagnostic entity, such as the PSP-Parkinson clinical subtype that is present in about 33% of PSP series, 11 may provide additional challenges not only for the neurologist but also for the PET scan interpreter.
Unlike clinical practice, where the accuracy of clinical APS diagnosis tends to improve with longer duration of disease follow-up, Hellwig et al. found that functional imaging may perform equally well or even better with shorter duration of the disease process. Thus, the real advantage of molecular brain imaging in the differential diagnosis of APS is that it may improve diagnostic accuracy at a time when it is most needed for the movement disorders neurologist and the newly diagnosed patient.
